Abstract
Delayed Dark Adapted vision Recovery (DAR) is a biomarker for Age-related Macular Degeneration (AMD), however its measurement is burdensome for patients and examiners. We developed a portable, wireless, quick-setup system that employs a headset with a smartphone to deliver controlled photobleach and monocular pattern reversal stimuli, while using custom electroencephalography (EEG) electrodes and electronics in order to measure objective Dark Adapted Visual Evoked Potentials (DAVEP) at multiple locations of the visual field - all in one comfortable 20-minute session, without requiring subject reporting. DAVEP responses post photobleach (up to 15 minutes), were measured concurrently in both eyes of 13 patients with AMD and 8 others not diagnosed with AMD. New, unexpected features at high latencies were observed in the DAVEP responses to scotopic stimulus intensities. The amplitude recovery of the DAVEP response was significantly delayed in AMD patients compared with controls. We developed DAVEP1 scores, a simple metric for DAR, using it to successfully identify all 100% of AMD subjects and classify 90% of subject eyes correctly. Deficits in DAR in patients with AMD can be identified using this objective VEP based system and the DAVEP1 metric, a promising new objective biomarker for this disease that can be easily tested in a clinic.
Competing Interest Statement
SK None. KL None. SAB None. PB Research Support, NeuroFieldz Inc, Newton, MA. CV Research Support, NeuroFieldz Inc, Newton, MA. Patent, Northeastern University SS Research Support, NeuroFieldz Inc, Newton, MA. Patent, Northeastern University
Funding Statement
Work partially supported by grant HHS-1R41AG057250-01.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
De-identified data sets may be made available upon request to the corresponding author via email (cversek{at}gmail.com).
